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Abstract
Background: Antioxidant and anti-inflammatory properties of honey have been largely recognized by various
studies. Almost all of the potential benefits are associated with polyphenol content. Honey varieties from the arid
region are reported to be rich in polyphenols, but data related to its bioactivity in vitro is greatly lacking. This study
aimed at establishing the antioxidant and anti-inflammatory properties of arid region honey. Four honey varieties
from arid region (H1, H2, H3, and H4) and two popular non-arid region honey (H5 and H6) were tested in vitro in
this study.
Methods: The erythrocyte membrane protection effect of honey varieties were measured by hemolysis assay after
exposing erythrocytes to a peroxide generator. The subsequent production of MDA (malondialdehyde) content in
erythrocytes was measured. Immunomodulatory effect of the honey varieties was tested in prostate cancer cells PC-
3 and PBMC (peripheral blood mononuclear cells) by measuring the IL-6 (interleukin 6) and NO (nitric oxide) levels
in cell culture supernatant after incubation with the honey varieties. PC-3 cell viability was assessed after incubation
with honey varieties for 24 h.
Results: Arid region honey exhibited superior erythrocyte membrane protection effect with H4 measuring 1.3 ± 0.
042mMTE/g and H2 measuring 1.122 ± 0.018mMTE/g. MDA levels were significantly reduced by honey samples,
especially H4 (20.819 ± 0.63 nmol/mg protein). We observed a significant decrease in cell population in PC-3 after
24 h in culture on treatment with honey. A moderate increase in NO levels was observed in both cultures after
24 h at the same time levels of IL-6 were remarkably reduced by honey varieties.
Conclusion: The results demonstrate the antioxidant effect of arid region honey due to its erythrocyte membrane
protection effect and subsequent lowering of oxidative damage as evident from lower levels of lipid peroxidation
byproduct MDA. Arid region honey varieties were as good as non-arid region types at decreasing cell viability of
prostate cancer cells. The moderate increase in NO levels in PC-3 and PBMCs were not significant enough to elicit
any pro-inflammatory response. However, IL-6 secretion was remarkably reduced by all honey varieties in a
comparable level indicating the potential anti-inflammatory property of arid region honey.
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Background
Honey is a viscous liquid produced by bees from the nectar
of flowers. It is considered as a wholesome natural food
and is also put to medicinal use. Honey has been shown to
have broad spectrum anti-microbial activity against gram
positive and gram negative bacteria [1] and it is also re-
ported to have wound healing capabilities [2]. Many aspects
of honey’s healing properties have been identified, including
antioxidant, anti-inflammatory and anti-tumor properties
[2, 3]. These health properties are of great interest since
oxidative stress and inflammation are mechanisms involved
in the development of major chronic diseases like cancer
[4]. A strong relationship between oxidative stress and
inflammation is highly suspected, where the inflammatory
process could be activated by a pro-oxidant condition
which yet again triggers the release of additional ROS (re-
active oxygen species) [4, 5]. Chronic diseases are increas-
ing throughout the world and a marked increase in chronic
disease has been identified in the Arab Gulf Region [6].
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Oxidative stress is defined as an imbalance between the
production of free radicals and reactive metabolites, so-
called oxidants or ROS. Protective mechanisms during
metabolic reactions involve antioxidants which act mainly
as ROS scavengers. The imbalance between oxidative
stress and antioxidant scavengers leads to damage of im-
portant biomolecules in the cells. Lipids are one biomol-
ecule that represent a significant target for ROS attack.
The lipid peroxidation generates other reactive species
such as MDA and can increase the risk of mutagenesis.
Cancer initiation and progression have been linked to oxi-
dative stress by increasing DNA mutations or inducing
DNA damage, genome instability, and cell proliferation
[7]. ROS scavenger activity and improvement of the anti-
oxidant status are some of the mechanisms by which
honey could exert its antioxidant action [8].
Inflammation is another condition which has been re-
lated to the etiology and the development of cancer.
Prostate cancer is expected to be one of the major dis-
ease in males in the coming decades [6]. There is grow-
ing evidence for an implication of chronic inflammation
in the origin of many cancers including prostate cancer.
Inflammation leads to the release of pro-inflammatory
cytokines, particularly IL-6 and NO. They are shown to
contribute to the damage of macromolecules and cells,
disruption of the cell division process and the transform-
ation of a normal cell to a tumor cell. IL-6 was clearly
identified as a key cytokine implicated in cancers of
prostatic tissue, breast tissue, and colorectal tissues [9,
10]. Recently, PBMCs, the active lymphocyte and mono-
cyte fraction of the blood, were shown to be associated
with prostate cancer development, through the secretion
of pro-inflammatory cytokines most notably IL-6 [11].
A more complex and multifaceted role of IL-6 and NO
related to inflammation has been identified. NO was
shown to act as a pro-inflammatory or anti-inflammatory
agent, depending upon the site of release and its concen-
trations [12]. There is growing evidence of an immuno-
modulatory effect of honey [13–15]. A modulation of IL-6
and NO secretion with honey treatment was observed
through in vitro and in vivo studies [8]. Due to its action
on the oxidative balance and inflammatory process, honey
was shown to modulate the initiation and the progression
of many types of cancer among which breast, liver, and
colon cancer have been extensively studied [8, 16, 17]. In
spite of very promising data, honey’s effect on prostate
cancer remains to be better explored.
It is now recognized that almost all of the biological
activity of honey is credited to its composition [18]. This
natural product has a complex chemical composition.
All honey types are a mixture of sugars, bee proteins, vi-
tamins, minerals, and polyphenols. Most of the antioxi-
dant benefits of honey are associated with the presence
of polyphenols [19]. There is a high correlation between
honey’s biological activity and the polyphenolic content.
Polyphenols are secondary metabolites of plants that act
as dietary antioxidants in the body. More than 8000
compounds have been identified hitherto, and some of
them like curcumin and catechins are extensively
researched for potential therapeutic applications. The
common polyphenols reported in honey include gallic
acid, catechins, epicatechins, chlorogenic acids, caffeic
acids, coumaric acids and quercetin [20]. The content of
these polyphenols is different depending on the source
and floral origin of honey. The climate where honey is
made also significantly influences the polyphenol content
and profile. Notably, it was demonstrated that some arid
region honey possess a greater amount of polyphenols
compared to famous non-arid region honey [21, 22].
Knowing this, it is reasonable to expect from arid region
honey greater health benefits. Habib et al. [21] reported
that one or more types of honey from arid regions pre-
sented a higher antioxidant potential compared to non-
arid region honey varieties. Habib et al. [21] compared
non arid region honey varieties such as Black Forest and
Manuka to arid region honey by using biochemical assays.
Non-arid region varieties of honey such as Manuka [23],
Gelam [16] and Tualang [24] have been extensively stud-
ied in regards to their antioxidant, anti-inflammatory and
anti-tumor properties. Results from these studies were
promising. However, arid region honey in spite of their
high polyphenolic content and greater antioxidant effect,
which are both in favor of an anti-tumor effect, remain
uninvestigated for their biological activity. Thus further
exploration of the health properties of arid region honey is
warranted. The aim of this research is to investigate the
potential antioxidant, anti-inflammatory, and anti-tumor
properties of some of the most popular varieties of arid re-
gion honey, and to compare arid region honey to popular
non-arid region honey varieties.
Methods
Materials
Histopaque-1077, PBS (phosphate buffered saline), AAPH
(2, 2’-azo-bis (2-amidinopropane) dihydrochloride), Tro-
lox, and Trypan blue solution from Sigma-Aldrich; RPMI
1640, FBS (fetal bovine serum), and Penicillin-
Streptomycin cocktail from Gibco; Bovine Hypothalamus
Extract prepared in-house as per the method described by
Maciag et al. [25]; Griess Reagent Kit for Nitrite Deter-
mination from Molecular Probes; IL-6 ELISA Kit from
Novex, Life Technologies.
Honey varieties
All honey varieties used for the study were purchased
from local supermarkets. Honey varieties were selected
for in vitro analysis based on the results reported by
Habib et al. [21]. Four honey varieties were selected
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from the arid region, two monofloral (H1 and H3) and
two heterofloral (H2 and H4), to compare with two non-
arid region varieties H5 (monofloral) and H6 (hetero-
floral). All details about each of these honey types are
described in Table 1. For hemolysis and MDA assay,
honey varieties were dissolved in PBS to make 10% solu-
tion. For anti-inflammatory studies and cell viability test,
10% honey solution was prepared by dissolving in serum
free media. The honey solutions were centrifuged at
3000 × g for 10 min to remove any undissolved particles
and filtered using 0.45 μm membrane filter.
Hemolysis assay
Erythrocyte membrane protection effect of the honey
varieties was measured using the method described by
Banerjee et al. [26] with some modifications. Briefly,
whole blood was collected from a healthy donor in
EDTA tubes and was centrifuged at 750 × g for 5 min at
room temperature to separate the platelet rich plasma.
The erythrocytes were washed twice with PBS, and a 5%
suspension of the erythrocytes was prepared in PBS for
the assay. 500 μl of the 5% erythrocyte suspension was
exposed to 200 μl of 10% honey samples (v/v in PBS) or
200 μl of Trolox standards for 30 min at 37 °C. AAPH
was added to the samples to attain a concentration of
50 mM in solution, and the tubes were further incubated
for further 2 h at 37 °C. The samples were centrifuged at
3000 × g for 10 min and supernatant was collected. The
absorbance of the supernatant was measured using a
UV-Visible spectrophotometer at wavelength 540 nm.
The experiment was carried out in triplicates and data
were expressed as mM Trolox Equivalent (TE)/g.
MDA assay
The decrease of MDA content by honey in erythrocytes
after incubation with peroxide generator AAPH was
measured by TBARS (Thiobarbituric acid reactive sub-
strates) method described earlier by Seljeskog et al. [27]
with some modifications. 500 μl of 5% erythrocyte sus-
pension prepared in PBS was incubated with 200 μl of
honey varieties H1, H2, H3, H4, H5, H6 (10% v/v in
PBS) or 40 mM Trolox (positive control) or PBS. After
30 min incubation AAPH was added to the samples to
attain a concentration of 50 mM in solution and the
mixture was incubated for 2 h at 37 °C. The control used
for the experiment was erythrocyte suspension incubated
with PBS and treated with AAPH. Following incubation,
an equal volume of deionized water was used to lyse the
cells. Erythrocyte suspension was directly lysed with de-
ionized water to measure the native MDA content in the
cells. The samples were then subjected to protein pre-
cipitation using 20% TCA and centrifuged at high speed
to separate the protein. The supernatant was aliquoted
to new tubes and were incubated with 0.4% TBA (Thio-
barbituric acid, w/v in 0.2 N HCl) at 60 °C for one hour
for the formation of TBA-MDA adducts. The TBA-
MDA adduct formed in the sample was measured by
Breeze HPLC System (Waters, USA). The mobile phase
was methanol:0.05 M KH2PO4 buffer pH 6.8 (40:60, v/v)
containing 0.2% (v/v) triethanolamine. Xterra MS C18
reverse phase column of 5 μm pore size was used for the
analysis. The column temperature was 35 °C, and the
flow rate was 1 ml/min with an injection volume of
20 μl. The fluorescence detection wavelength was set at
532 nm (excitation) and 553 nm (emission). All samples
were analysed in triplicates.
PBMC isolation and culture
PBMCs were isolated from whole blood using density
gradient centrifugation in Histopaque-1077 as per man-
ufacturer’s protocol. Briefly, blood samples were ob-
tained from healthy donors in EDTA tubes and diluted
with equal volume of PBS and layered over Histopaque
and centrifuged at 400 × g for 30 min at room
temperature in a bench top centrifuge. The layer con-
taining PBMCs were carefully separated from the Histo-
paque interface and washed twice with serum-free RPMI
1640 medium by centrifuging at 250 × g for 10 min. The
washed PBMCs were resuspended in RPMI 1640
substituted with 10% FBS, 100u/ml penicillin, 100 μg/ml
streptomycin and 25 μg/ml bovine hypothalamus extract
and maintained at 37 °C in 5% CO2 incubator.
Table 1 Description of honey varieties by region
Sample Type Family Botanical name Common name Country
Arid region
H1 Monofloral Rhamnaccae Ziziphus spina-csisti Wild jujube United Arab Emirates
H2 Heterofloral Fabaceae Acacia tortilis Wild mountain Yemen
H3 Monofloral Fabaceae Acacia tortilis Wild mountain United Arab Emirates
H4 Heterofloral Fabaceae Acacia tortilis Mountain herbal Yemen
Non arid region
H5 Monofloral Myrtaceae Leptospermum scorparium Manuka New Zealand
H6 Heterofloral Myrtaceae Leptospermum scoparium Black forest Germany
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PC-3 culture
Prostate cancer cell line, PC-3 was purchased from
European Collection of Authenticated Cell Cultures
(ECACC), UK and was cultured in RPMI 1640 medium
substituted with 10% FBS, 100U/ml Penicillin and
100 μg/ml Streptomycin. Upon reaching 80% confluence,
the cells were passaged using 0.25% Trypsin.
Anti-inflammatory properties
PC-3 cells and PBMCs were seeded at a density of 4 ×
105 cell/ml in six-well plates, and grown to 80% con-
fluency in complete growth medium (RPMI 1640
substituted with 10% FBS, 100u/ml penicillin, 100 μg/ml
streptomycin and 25 μg/ml bovine hypothalamus extract
for PBMCs and RPMI 1640 medium substituted with
10% FBS, 100U/ml Penicillin and 100 μg/ml Strepto-
mycin for PC-3). Upon reaching 80% confluency, the
cells were starved overnight with serum-free media and
subsequently medium substituted with 10% honey solu-
tion was introduced to cells. The culture was incubated
for 24 h at 37 °C in 5% CO2 incubator, following which
the culture supernatant was retrieved for the experi-
ments. The IL-6 and NO levels in PC-3 and PBMC cul-
ture supernatants were measured by commercial ELISA
kit and Griess reaction method respectively. Untreated
cells grown in respective complete growth medium
served as control for the experiments. All experiments
were carried out in triplicates.
Viability test
Ten percent honey samples were prepared in serum-free
media and filter sterilized. PC-3 cells were seeded at a
density of 4 × 105 cell/ml in six-well plates, upon reaching
80% confluency, the cells were starved overnight with
serum-free media following which medium containing
10% honey was introduced to cells. The culture was incu-
bated for 24 h at 37 °C in 5% CO2 incubator. Post incuba-
tion the viability was assessed by trypan blue exclusion
assay, and percentage viability was calculated. Experi-
ments were carried out in triplicates, and untreated cells
grown in complete growth medium was used as control.
Statistical analysis
All data are presented as mean ± SD. Statistical analysis
was done by Post Hoc Tukey Test using SPSS statistical
software version 20 for all quantitative parameters to
identify the significance of the difference between con-




Membrane protection effect was used to demonstrate
antioxidant activity of the honey varieties. Table 2 shows
the results from the hemolysis assay. In this assay, per-
oxide generator AAPH was added to cells to induce lysis
and decrease in hemolysis by honey treatment was mea-
sured in terms of trolox equivalents. All honey varieties
were found to be effective in protecting the erythro-
cyte membrane from oxidative damage. In this study,
H4 showed the highest antioxidant activity at 1.3 ±
0.042mMTE/g. This is significantly higher than all
other samples except H2. Sample H2 was second in
effectively preventing hemolysis indicating a higher
antioxidant effect at 1.122 ± 0.018mMTE/g. Interest-
ingly, the antioxidant potential of both H2 and H4
was significantly higher than both non-arid region
types H5 and H6, measuring 0.907 ± 0.053mMTE/g
and 0.668 ± 0.040mMTE/g respectively. The lowest
measured antioxidant effect which stood at 0.668 ±
0.040mMTE/g was observed in H6. In comparison H1
and H3 showed significantly higher erythrocyte mem-
brane protection effect than H6, with 1.046 ±
0.089mMTE/g and 1.014 ± 0.044mMTE/g, respectively.
MDA assay
All honey varieties significantly reduced the amount of
MDA content formed as a result of peroxyl radicals
generated by AAPH (Fig. 1) when compared to the con-
trol group (AAPH in Fig. 1). The positive control of the
experiment, Trolox, in combination with AAPH, showed
a significant lowering of MDA levels with 13.23 ±
1.12 nmol/mg protein. This was significantly lower than
the control and all honey varieties. Arid region honey
H4 demonstrated the overall best antioxidant effect with
a measured MDA level of 20.819 ± 0.63 nmol/mg protein
which indicates its ability to lower oxidative damages
than both non-arid region varieties H5 (25.11 ±
0.42 nmol/mg protein) and H6 (25.98 ± 0.44 nmol/mg
protein). All other honey varieties presented a compar-
able effect in reducing oxidative damage to erythrocytes.
Table 2 Anti-hemolytic effect of honey varieties (mM Trolox
Equivalent/g)
Samlple mM Trolox Equivalent/g
H1 1.046 ± 0.089 a
H2 1.122 ± 0.018 b
H3 1.014 ± 0.044 c
H4 1.30 ± 0.042 d
H5 0.907 ± 0.053
H6 0.668 ± 0.040 e
Means ± s.e. are presented
aSignificant difference between H1 and H4
b Significant difference between H2 and H5
cSignificant difference between H3 and H4
dSignificant difference between H4 and H5
eSignificantly lower than all honey varieties
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Nitric oxide levels
Nitric oxide level in both PBMC and PC-3 cultures are
presented in Fig. 2. The levels detected in PBMCs were
significantly higher in all honey varieties except H1 and
H3 in which percentage detected was similar to control
group. Among the arid region honey, the percentage of
NO in H2 was the highest at 242.03% ± 9.97%. The level
of NO in H4 treated group in PBMCs was also increased
at 160.09% ± 3.58%. Interestingly, both H2 and H4 are
heterofloral varieties. PBMCs elicited the highest re-
sponse in H6 group, which was significantly higher than
all other groups, in which the measured percentage of
NO level was 289.70% ± 19.99%. Only H2 in the arid re-
gion had a comparable effect in PBMCs as seen in H6.
The effect of H5 on PBMCs measuring 177.17% ± 5.64%
was only slightly higher than H4. However, NO levels in
H1 and H3 was much lower than H5. PC-3 culture
showed the remarkable result in NO production in treat-
ment with the honey samples. The effect of each honey
type in the PC-3 cell was different from that of PBMCs.
Here, all groups except H3 and H6 gave a significantly
higher increase in NO production when compared to
control. Unlike the response in PBMCs, H1 recorded the
highest percentage increase in NO at 318.16% ± 7.38%
and H6 recorded the least increase at 117.94% ± 17.32%.
The level of NO increase seen in H1 groups was similar
to H5 which stood at 311.47% ± 19.38%. This is clear in-
dication that arid region honey H1 has a comparable ef-
fect to that of non-arid region honey H5. The effect of
H2 (216.39% ± 17.71%) and H4 239.89% ± 47.14%) was
Fig. 1 Malondialdehyde content measured by TBARS assay in erythrocytes after treatment. Data expressed as nmol MDA/mg protein. Normal
represented the amount of MDA in erythrocytes without treatment. Normal and AAPH + Trolox were used as positive controls for the experiment.
Comparisons using Post Hoc Tukey test was carried out for AAPH, H1, H2, H3, H4, H5, and H6. *Significant decrease in MDA levels compared to
AAPH treated group. a - Significant difference in MDA levels between H4 and H6. b - Significant difference between H5 and H6
Fig. 2 Nitric oxide concentration after 24-h incubation with honey varieties. Data expressed as percentage of control. *Significant difference in
NO levels observed between groups. a - Significant increase of NO levels in H6 treated groups in comparison to all honey varieties and control in
PBMCs. b - Significant lowering of NO level in H6 treated groups in comparison to H1, H2, H4, and H5 in PC-3
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however significantly better than that of H6 non-arid honey.
The response from H3 (159.55% ±2.3%) measured was
higher than control and H6 although it was not significant.
IL-6 ELISA
IL-6 secretion by PBMCs and PC-3 cells were lowered
when compared to control on treatment with the honey
(Fig. 3). The percentage of IL-6 secretion in PBMCs, how-
ever, was significantly lowered only in H1 (74.56% ± 5.25%),
H3 (83.57% ± 4%) and H6 (77.87% ± 0.66%). Arid region
honey H1 elicited the most effective reduction in PBMCs,
and the measured percentage was comparable with non-
arid region variety. Meanwhile, H5 (97.49% ± 2.93%) gave
the least effect in the study. The response induced by H2
(93.23% ± 2.8%) and H4 (89.92% ± 5.4%) from the arid re-
gion markedly better than H5, however, were not signifi-
cant. From arid region honey, the monofloral varieties (H1
and H3) elicited great reduction when compared to a simi-
lar variety from the non-arid region (H5). The percentage
secretion of IL-6 by PC-3 cells was considerably lowered in
comparison to control. In all groups, the data was signifi-
cantly lower than the control. All honey varieties showed a
similar effect in lowering the IL-6 secretion from PC-3,
there were not significantly different from each other.
Cell viability
After 24-h incubation with honey varieties, there was a
marked difference in the morphology of the PC-3 cells
treated with honey compared to that of the control
(Fig. 4a–g). The honey-treated group appeared to be
more rounded and shrunk in size compared to the un-
treated group which appeared elongated and stretched
which is characteristic to PC-3 cells. The viability of the
cells in the honey treated group was found to be signifi-
cantly lower compared to the control (Fig. 4h). The
viability of PC-3 cells was effectively reduced by all arid
region varieties. H1 was the most effective honey variety
in lowering viability to 66.89% ± 2.76% which was signifi-
cantly better than H3 which has the least capacity in
lowering viability measuring 76.08% ± 4.4%.
Discussion
This in vitro study investigated the antioxidant, anti-
inflammatory and anti-tumor properties of the popular
honey varieties from the arid region. For the study, two
monofloral (H1 and H3) and two heterofloral (H2 and
H4) varieties of honey were selected from arid region to
compare with popular monofloral and heterofloral var-
ieties from the non-arid region, namely Manuka and
Black Forest (H5 and H6, respectively). Globally, antioxi-
dant, anti-inflammatory and anti-tumor effects were
demonstrated for arid region honey. Arid region honey
showed a greater antioxidant effect than non-arid honey
as shown by the prevention of oxidative damages to
erythrocytes. The variety H4, a heterofloral mountain
herbal variety from Yemen, was the most effective in
lowering erythrocyte lysis by peroxide radicals whereas
all other arid region varieties showed comparable effect
to non-arid region varieties. Reduction of lipid peroxida-
tion as seen by lowering of MDA levels by H4 also indi-
cates its superior ability is lowering oxidative damage.
Decrease in IL-6 level was observed, in a similar way, in
arid and non-arid region honey indicating comparable
anti-inflammatory effect of the varieties. One of the
most significant results noted was the reduced viability
of PC-3 cells on treatment with the honey varieties, indi-
cating its potential anti-tumor effect.
The free radical-induced erythrocytes hemolysis is rec-
ognized as a particularly efficient method for evaluation
of antioxidant capacity, with some advantages compared
Fig. 3 IL-6 concentration after 24-h incubation with honey varieties. Data expressed as percentage of control. *Significant difference in
IL-6 concentration observed between treatment groups in PBMCs. # Significant lowering of IL-6 concentration in honey treated groups
compared to control in PC-3 cells
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to common biochemical assays like TAC or DPPH. It
uses free radicals as pro-oxidants and erythrocytes as
oxidizable targets so that the results obtained reflect bio-
logically relevant radical-scavenging activity. Lysis of
erythrocytes, which transport oxygen and are one of the
most abundant cells in the human body, is related to oxi-
dative stress. Free Radicals, generated by this oxidative
stress, are known to attack highly unsaturated fatty acids
to induce lipid peroxidation, leading to changes in the flu-
idity of the cell membrane and ultimately to cell injury
and lysis. Erythrocytes are more likely to be exposed to
this type of oxidative damage due to high lipid content in
their membranes and presence of transition metals like
iron and copper. Arid region honey demonstrated a pro-
tection effect to erythrocytes against lysis by free radicals
generated by AAPH. Similar results were observed in an
in vivo study where enhanced cytoprotective function was
demonstrated against doxorubicin toxicity in mice supple-
mented with Seder mountain honey [28].
Also, arid region honey was able to protect against lipid
peroxidation in erythrocytes. Erythrocytes hemolysis is re-
lated to oxidative damages on lipid bilayer. One of the
principle markers of oxidative damage in erythrocyte is
the lipid peroxidation product MDA. An increase in MDA
level will be observed in cells that are exposed to free radi-
cals. Therefore, an effective lowering of MDA levels by
honey varieties supports its antioxidant property. While
such an antioxidant effect had already been shown by
Habib et al. [21], in arid region honey, it was done by
using common biochemical assays (DPPH, FRAP, TAC)
and not cell-based tests.
The anti-inflammatory effect of honey was long estab-
lished through various studies [14, 16, 23, 29] on non-arid
region honey, yet nothing was available on arid region var-
ieties. The research results demonstrated here indicate
that arid region honey also possesses anti-inflammatory
effects similar to previously studied non-arid honey types.
This is demostrated by its capacity to lower IL-6 in
Fig. 4 Viability of PC-3 cells after 24-h incubation with honey. a Untreated Control, b H1, c H2, d H3, e H4, f H5, g H6. Cell under 20X magnifica-
tion. h Percentage decrease in viability of cells after 24-h incubation with honey varieties. *Treatment groups shows significant lowering of viabil-
ity compared to control. # - Significant difference between H1 and H3
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prostate cancer cell line and PBMCs. IL-6, as an early sig-
nal, is a key component in the inflammatory process. It is
secreted by T cells and macrophages to stimulate inflam-
mation at the time of infection or tissue damage. It is
noteworthy that all honey types were equal in their ability
to lower the cytokine level in both cell types. In PBMCs,
the decrease in IL-6 levels, however, was not as remark-
able as PC-3. This can be related to the fact that prostatic
cancer tissue secretes cytokine IL-6 in great quantities and
that PBMCs were under normal conditions. As reported
earlier expression of IL-6 is associated with the develop-
ment of prostate cancer through an immunomodulatory
dialog with cancer cells [11]. The result observed in this
study takes precedence as it clearly demonstrates an im-
munomodulatory effect in prostate cancer cell line. Con-
sidering that health properties of honey were related to
their polyphenol content, the result of this study are in ac-
cordance with the recent study in which treatment with
polyphenols were able to lower the expression of pro-
inflmmatory cytokines in PBMCs [30].
Surprisingly, where an anti-inflammatory effect of honey
could be suggested based on the data of IL-6, the effect of
honey on NO production was apparently in favor of a pro-
inflammatory action. Indeed, it was found that all honey
varieties were capable of increasing the NO levels in varying
degrees in PC-3 cells and PBMC, which accounts for initi-
ation of systemic pro-inflammatory response. NO, which is
an important mediator of inflammation, is a double-edged
compound, playing a paradoxical role depending upon the
concentration at which it is secreted by cells. Typically,
under low physiological concentration, NO acts as an anti-
inflammatory molecule, but at higher concentration it acts
as a mediator of inflammation [12]. Here, the increase of
NO production was least in both cultures on treatment
with arid region variety H3. On the contrary, the non-arid
region types gave varying data in both cultures, where H6
gave a significant increase of NO in PBMCs while the in-
crease was minimal in PC-3 cells. However in both cell
types studied, an increase of NO by a 0.6–2 μM from the
control concentration was observed, this cannot be signifi-
cant enough to be considered pro-inflammatory as it is re-
ported that a 100 fold increase is at least observed at the
time of pro-inflammatory signaling by NO [31, 32]. There-
fore, it seems that the increase of NO levels which was de-
tected in our study was not strong enough to elicit any pro-
inflammatory response.
Finally, since oxidative stress and inflammation are
two major mechanisms involved in the etiology and de-
velopment of cancer [4], the research results identified
here indicate that arid region honey could effectively
regulate growth and metastasis of prostate cancer cells.
This is supported by our result which have shown that
IL-6 was reduced with supplementation of honey in PC-
3 cells. IL-6 is associated with aggressive prostate cancer
phenotype and may be involved in the metastatic
process through regulation of epithelial-mesenchymal
transition and homing of cancer cells to the bone [9]. It
is also interesting to note that in vivo studies in animals
and human clinical trials have been conducted with anti-
IL-6 monoclonal antibodies to target prostate tumor
[33]. This would mean that any factor able to reduce the
secretion of IL-6 could exert an anti-tumor action. In
addition, we found the viability of PC-3 cells was re-
duced on treatment with honey for 24 h. The capacity of
honey observed in this study, (both arid and non-arid re-
gion varieties) to significantly reduce the population of
PC-3 cells and reduce its capacity to secrete IL-6, en-
ables us to suggest a possible anti-tumor effect for honey
in prostate cancer.
A tight inter-relationship between oxidative stress and
inflammation is now well acknowledged [34]. However,
the sequence of these events remains unclear and im-
pedes the identification of therapeutic targets. Some
studies clearly showed that one of the important aspects
of inflammation is the sudden increase in the superox-
ides, also called oxidative burst, as a result of phagocyte
activation. Also, it was observed that heme released by
erythrocytes as a result of lysis lead to neutrophil migra-
tion and triggered oxidative burst by these cells [35].
The capacity of antioxidants to protect the integrity of
the cell membrane was found to be a very critical event
in preventing inflammation, indicating that oxidative
damages would be the one to induce the inflammatory
process. The present study suggest that honey increased
protection of erythrocytes against lysis through the re-
duction of lipid peroxidation. This supports the theory
of the antioxidant effect in honey.
Globally, our results are significant in the context that
accumulation of oxidative damages in the body can later
result in the development of most chronic diseases. The
erythrocyte membrane protective function of honey can
effectively reduce the risk of inflammation from hemolysis
which has been implicated in several diseases leading to
organ damage. For example, the cytoprotective effect of
Seder honey variety, from the arid region, was assessed in
doxorubicin-treated mice [28]. In this study, enhanced
liver function and improvement in symptoms such as
bleeding were demonstrated in the treated groups.
In view of the fact that polyphenols in honey are re-
ported to have antioxidant and anti-inflammatory effects
[36–38], it can be reasonably assumed that similar re-
sults would occur using the honey varieties from arid re-
gion which have high polyphenol content. A more
comprehensive study on the polyphenol content of these
varieties would demonstrate which molecules are dir-
ectly involved in bringing about this effect. An earlier
study by Habib et al. [21] had probed more than ten arid
region varieties against non-arid region types showing
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the polyphenol content in the honey were comparable and
in some varieties even better than non-arid region var-
ieties. Greater health effects of arid region honey would be
expected if a higher polyphenol content is present. Here,
under in vitro conditions, the antioxidant potential of arid
region honey was either comparable or stronger, in case of
H4, than non-arid region varieties. The anti-inflammatory
and anti-tumor properties of the arid region were found
to be comparable to non-arid region types.
This work is presenting some limitations. One limitation
was related to the concentration of honey and the time of
cell exposure to honey. This could be addressed by prob-
ing the different concentrations of honey varieties used in
this study (concentration of honey used in our study was
10% which was calculated based on results reported from
the study by Habib et al.) and by assessing the long-term
effect of honey supplementation in cell culture. Further
experiments should be performed to clarify the anti-
inflammatory role of arid region honey, including the
study of additional cytokines like TNF-alpha, in PBMCs
after inducing inflammation.
Conclusions
Results obtained from our study has demonstrated that arid
region honey is a potential antioxidant, anti-inflammatory
and anti-tumor agent, as shown by the study of erythrocyte
lysis, erythrocyte membrane protection against oxidative
damages, cancer cell growth inhibition, and reduction of
pro-inflammatory marker secretion in PC-3 and PBMC
culture. Compared to non-arid region varieties, arid region
honey showed a greater antioxidant potential and compar-
able anti-inflammatory and anti-tumor effect. An immuno-
modulatory effect of arid region and non-arid region honey
was further suggested. All of this is in favor of a promising
use of arid region honey as a therapeutic product for major
chronic diseases, especially cancer.
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